Comparing the current results to its competitors, Unicycive Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 14.3 %, recorded in the same quarter.
Unicycive Therapeutics Inc, slower than the average decrease reported by the company's competitors of -87.19 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -87.19 %
Unicycive Therapeutics Inc's Comment on Competition and Industry Peers
The hyperphosphatemia treatment market is highly competitive, featuring established standard-of-care products from both biopharmaceutical innovators and generic manufacturers. Key competitor products include Renvela®/Renagel® (sevelamer), Fosrenol® (lanthanum carbonate), Velphoro®, Auryxia®, Xphozah® (tenapanor), and PhosLo® (calcium acetate). OLC (Oxylanthanum Carbonate) seeks to differentiate its product by offering a lower pill burden, eliminating the need for chewable administration, reducing iron-overload concerns, and being calcium-free to mitigate vascular calcification risks. Additionally, OLC claims a superior potency-to-volume ratio and an improved patient experience relative to existing treatments. The company recognizes competition from large, well-financed pharmaceutical and biotechnology firms developing similar or competing therapies for hyperphosphatemia.
September 3, 2024
Unicycive Therapeutics Announces NDA Submission to U.S. FDA for Innovative Phosphate Binder Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company dedicated to the development of therapies for kidney disease, has recently made an important stride in its mission to improve the lives of patients suffering from chronic kidney disease (CKD). On September 3rd, 2024, the company announced that it had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC), a novel phosphate binder aimed at managing hyperphosphatemia in CKD patients on dialysis. Hyperphosphatemia, an elevated level of phosphate in the blood, is a common and ...
July 10, 2024
Unicycive Therapeutics, a clinical-stage biotechnology company, has recently released positive patient satisfaction findings from a pivotal clinical trial of Oxylanthanum Carbonate (OLC). Patients participating in the trial expressed a strong preference for OLC over their prior phosphate binder therapy. Additionally, the company has presented data demonstrating the bioequivalence of OLC to Lanthanum Carbonate, further supporting the potential of this new therapy. Multiple presentations featuring OLC and another product candidate, UNI-494, will be delivered at the upcoming European Renal Association Congress, highlighting the significant progress in the field of kidney disease treatment.Patient Satisfaction w...
Unicycive Therapeutics, a leading biopharmaceutical company, recently announced a significant step forward in the treatment of Chronic Kidney Disease (CKD) on dialysis. By enrolling the first patient in a pivotal clinical trial for Oxylanthanum Carbonate (OLC), Unicycive aims to potentially revolutionize the management of CKD, providing hope for millions of affected individuals. With the study evaluating a cohort of 60 participants, the results are eagerly anticipated in the second quarter of 2024. Unprecedented Potential for Revolutionary Treatment: CKD is a chronic, progressive condition affecting the kidneys filtration ability, leading to the accumulation of toxins and waste in the body...
Publicly Traded Peers of Unicycive Therapeutics Inc
Acadia Pharmaceuticals Inc Share Performance
-5.07%
30 Days
Acadia Pharmaceuticals Inc
Profile
Acadia Pharmaceuticals Inc's business model centers around the research, development, and commercialization of innovative medicines for diseases related to the central nervous system. They collaborate with a network of partners and employ a combination of in-house research and licensing agreements to discover and develop drug candidates. Their primary revenue stream comes from the sales of approved products, with a focus on providing effective therapeutic options for patients with unmet medical needs.
Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Sources:
Unicycive Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Unicycive Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
